• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.

作者信息

Jiménez-Vicente Carlos, Martínez-Roca Alexandra, Pomares Helena, Castaño-Diez Sandra, Guijarro Francesca, López-Guerra Mònica, Bataller Alex, Esteban Daniel, Cortés-Bullich Albert, Pérez-Valencia Amanda Isabel, Guardia-Torrelles Ares, Zugasti Inés, Rovira Montserrat, Fernández-Avilés Francesc, Colomer Dolors, Arnan Montserrat, Díaz-Beyá Marina, Esteve Jordi

机构信息

Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; University of Barcelona, Barcelona, Spain.

Hematology Department, Hospital Clínic Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

出版信息

Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30.

DOI:10.1016/j.leukres.2023.107403
PMID:37837718
Abstract
摘要

相似文献

1
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.维奈托克与低甲基化药物联合使用，可能会根除急性髓系白血病（AML）中NPM1突变且CBF重排的患者在强化化疗后持续存在的可测量残留病（MRD）。
Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30.
2
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.分子 MRD 对接受维奈托克为基础的非强化治疗的 NPM1 突变 AML 患者具有很强的预后价值。
Blood. 2024 Jan 25;143(4):336-341. doi: 10.1182/blood.2023021579.
3
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.维奈托克联合低强度化疗诱导急性髓系白血病中 NPM1 突变型可测量残留病的快速消除。
Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26.
4
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.采用维奈托克和去甲基化药物治疗的异柠檬酸脱氢酶1/2（IDH1/2）突变急性髓系白血病（AML）患者中微小残留病（MRD）的反应模式及影响
Blood Cancer J. 2023 Sep 21;13(1):148. doi: 10.1038/s41408-023-00915-6.
5
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.基于 Venetoclax 的低强度治疗在 NPM1 突变型 AML 分子学复发中的应用。
Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106.
6
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).维奈托克与低甲基化药物（HMA）用于新诊断、复发或难治性KMT2A重排急性髓系白血病（AML）患者的临床经验
Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.
7
Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.伴有突变的急性髓系白血病中的微小残留病监测：临床观点和展望。
Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.
8
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.多基因可测量残留病通过数字聚合酶链反应评估，在接受维奈托克/阿扎胞苷治疗的急性髓系白血病患者中有临床和生物学应用。
Haematologica. 2024 Jun 1;109(6):1766-1778. doi: 10.3324/haematol.2023.283790.
9
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.维奈克拉/阿扎胞苷交替联合FLT3抑制剂治疗NPM1和FLT3突变的急性髓系白血病
Leuk Res. 2023 Jul;130:107313. doi: 10.1016/j.leukres.2023.107313. Epub 2023 May 16.
10
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.基因特征可预测复发或难治性急性髓系白血病对维奈克拉联合去甲基化药物的反应。
J Intern Med. 2023 Mar;293(3):329-339. doi: 10.1111/joim.13581. Epub 2022 Nov 3.

引用本文的文献

1
Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed acute myeloid leukemia.维奈托克联合低甲基化药物治疗新诊断和复发的急性髓系白血病
Haematologica. 2025 Jul 1;110(7):1639-1643. doi: 10.3324/haematol.2024.286836. Epub 2025 Feb 20.
2
At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.基于维奈克拉的低强度方案治疗急性髓系白血病诱导期患者的居家护理项目
Cancers (Basel). 2024 Dec 23;16(24):4274. doi: 10.3390/cancers16244274.
3
Optimal Post-Remission Consolidation Therapy in Patients with AML.
急性髓系白血病患者缓解后巩固治疗的最佳选择。
Acta Haematol. 2024;147(2):147-158. doi: 10.1159/000535457. Epub 2023 Nov 26.